Ensysce Biosciences, Inc. (ENSC)
NASDAQ: ENSC · IEX Real-Time Price · USD
0.570
-0.008 (-1.42%)
At close: May 24, 2024, 3:55 PM
0.561
-0.009 (-1.65%)
After-hours: May 24, 2024, 7:04 PM EDT

Company Description

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States.

It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.

The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis.

It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder.

The company was founded in 2003 and is based in La Jolla, California.

Ensysce Biosciences, Inc.
Ensysce Biosciences logo
Country United States
Founded 2003
Industry Biotechnology
Sector Healthcare
Employees 7
CEO Dr. D. Lynn Kirkpatrick Ph.D.

Contact Details

Address:
7946 Ivanhoe Avenue, Suite 201
La Jolla, California 92037
United States
Phone (858) 263-4196
Website ensysce.com

Stock Details

Ticker Symbol ENSC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001716947
CUSIP Number 293602108
ISIN Number US2936024056
Employer ID 82-2755287
SIC Code 2834

Key Executives

Name Position
Dr. D. Lynn Kirkpatrick Ph.D. President, Chief Executive Officer and Director
David C. Humphrey CPA Chief Financial Officer, Secretary and Treasurer
Geoffrey Birkett Chief Commercial Officer
Dr. Jeffrey Millard Ph.d. Chief Operating Officer
Dr. William K. Schmidt Ph.D. Chairman of Clinical Advisory Board and Chief Medical Officer
Dr. Linda Pestano Ph.D. Chief Development Officer

Latest SEC Filings

Date Type Title
May 13, 2024 8-K Current Report
May 13, 2024 10-Q Quarterly Report
May 9, 2024 8-K Current Report
May 1, 2024 EFFECT Notice of Effectiveness
Apr 19, 2024 POS AM Post-Effective amendments for registration statement
Apr 5, 2024 EFFECT Notice of Effectiveness
Mar 29, 2024 8-K Current Report
Mar 26, 2024 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Mar 15, 2024 8-K Current Report
Mar 15, 2024 10-K Annual Report